David Nierengarten
Stock Analyst at Wedbush
(4.45)
# 367
Out of 4,412 analysts
154
Total ratings
46.72%
Success rate
27%
Average return
Main Sectors:
Top Industries:
42 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Reiterates: Outperform | $110 | $93.00 | +18.28% | 2 | Apr 26, 2024 | |
| VOR Vor Biopharma | Reiterates: Outperform | $11 | $1.69 | +550.89% | 6 | Apr 23, 2024 | |
| TCRX TScan Therapeutics | Reiterates: Outperform | $10 | $7.32 | +36.61% | 3 | Apr 23, 2024 | |
| PRME Prime Medicine | Reiterates: Outperform | $12 | $4.43 | +171.19% | 3 | Apr 23, 2024 | |
| FATE Fate Therapeutics | Reiterates: Neutral | $7 | $3.80 | +84.21% | 10 | Apr 23, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Neutral | $29 | $20.76 | +39.69% | 4 | Apr 23, 2024 | |
| BEAM Beam Therapeutics | Reiterates: Outperform | $57 | $21.38 | +166.60% | 3 | Apr 23, 2024 | |
| ARGX argenx SE | Reiterates: Outperform | $521 | $372.80 | +39.75% | 11 | Apr 18, 2024 | |
| IMNM Immunome | Maintains: Outperform | $27 → $33 | $13.73 | +140.35% | 3 | Apr 1, 2024 | |
| STRO Sutro Biopharma | Maintains: Outperform | $12 → $8 | $3.42 | +133.92% | 5 | Mar 26, 2024 | |
| FUSN Fusion Pharmaceuticals | Reiterates: Neutral | $24 | $21.42 | +12.04% | 5 | Mar 21, 2024 | |
| BLUE bluebird bio | Maintains: Neutral | $3 → $1.68 | $0.92 | +82.05% | 1 | Mar 19, 2024 | |
| TSVT 2seventy bio | Reiterates: Neutral | $5 | $4.26 | +17.51% | 7 | Mar 18, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $20 | $8.07 | +147.83% | 4 | Mar 12, 2024 | |
| ANAB AnaptysBio | Upgrades: Outperform | $20 → $34 | $21.00 | +61.90% | 9 | Mar 12, 2024 | |
| GBIO Generation Bio Co. | Reiterates: Outperform | $5 | $2.90 | +72.41% | 6 | Mar 7, 2024 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $5 | $2.68 | +86.57% | 3 | Mar 1, 2024 | |
| MRSN Mersana Therapeutics | Upgrades: Outperform | $2 → $7 | $2.94 | +138.10% | 2 | Feb 29, 2024 | |
| XNCR Xencor | Maintains: Outperform | $36 → $34 | $19.98 | +70.17% | 5 | Feb 28, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Outperform | $60 → $70 | $45.53 | +53.74% | 2 | Feb 26, 2024 | |
| COGT Cogent Biosciences | Maintains: Neutral | $5 → $10 | $6.02 | +66.11% | 2 | Feb 23, 2024 | |
| GTHX G1 Therapeutics | Maintains: Outperform | $5 → $4 | $3.99 | +0.25% | 6 | Feb 13, 2024 | |
| INZY Inozyme Pharma | Reiterates: Outperform | $15 | $4.44 | +237.84% | 4 | Jan 30, 2024 | |
| IKNA Ikena Oncology | Reiterates: Outperform | $8 | $1.30 | +515.38% | 2 | Jan 19, 2024 | |
| KNSA Kiniksa Pharmaceuticals | Maintains: Outperform | $23 → $25 | $17.88 | +39.82% | 1 | Jan 2, 2024 | |
| MAXN Maxeon Solar Technologies | Maintains: Equal-Weight | $14 → $5 | $2.09 | +139.23% | 5 | Dec 8, 2023 | |
| ITOS iTeos Therapeutics | Reiterates: Outperform | $33 | $10.80 | +205.56% | 2 | Oct 18, 2023 | |
| CMRX Chimerix | Reiterates: Outperform | $6 | $0.90 | +566.74% | 2 | Aug 17, 2023 | |
| SRRK Scholar Rock Holding | Reiterates: Outperform | $24 | $14.53 | +65.18% | 5 | Aug 10, 2023 | |
| APGE Apogee Therapeutics | Initiates: Outperform | $40 | $47.13 | -15.13% | 1 | Aug 8, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Neutral | $7 → $4 | $1.06 | +277.36% | 5 | Jul 26, 2023 | |
| NUVL Nuvalent | Reiterates: Outperform | $53 | $66.86 | -20.73% | 2 | Jul 20, 2023 | |
| AVRO AVROBIO | Downgrades: Neutral | $2 | $1.21 | +65.29% | 1 | Jul 12, 2023 | |
| NVCR NovoCure | Upgrades: Neutral | $53 → $46 | $12.64 | +264.07% | 4 | Jun 7, 2023 | |
| YMAB Y-mAbs Therapeutics | Upgrades: Outperform | $5 → $13 | $14.71 | -11.62% | 2 | May 10, 2023 | |
| IRON Disc Medicine | Maintains: Outperform | $32 → $36 | $27.55 | +30.67% | 2 | Apr 26, 2023 | |
| FENC Fennec Pharmaceuticals | Maintains: Outperform | $11 → $19 | $9.21 | +106.30% | 3 | Sep 26, 2022 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | n/a | $44.24 | - | 6 | Oct 29, 2018 | |
| BOLD Boundless Bio | Maintains: Outperform | n/a | $11.64 | - | 1 | Oct 8, 2018 | |
| VYGR Voyager Therapeutics | Upgrades: Outperform | n/a | $7.62 | - | 2 | May 11, 2018 | |
| SYRS Syros Pharmaceuticals | Maintains: Outperform | n/a | $5.04 | - | 1 | Mar 13, 2018 | |
| PRTA Prothena Corporation | Downgrades: Neutral | n/a | $20.87 | - | 1 | Nov 20, 2017 |
Blueprint Medicines
Apr 26, 2024
Reiterates: Outperform
Price Target: $110
Current: $93.00
Upside: +18.28%
Vor Biopharma
Apr 23, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.69
Upside: +550.89%
TScan Therapeutics
Apr 23, 2024
Reiterates: Outperform
Price Target: $10
Current: $7.32
Upside: +36.61%
Prime Medicine
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.43
Upside: +171.19%
Fate Therapeutics
Apr 23, 2024
Reiterates: Neutral
Price Target: $7
Current: $3.80
Upside: +84.21%
Intellia Therapeutics
Apr 23, 2024
Reiterates: Neutral
Price Target: $29
Current: $20.76
Upside: +39.69%
Beam Therapeutics
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $21.38
Upside: +166.60%
argenx SE
Apr 18, 2024
Reiterates: Outperform
Price Target: $521
Current: $372.80
Upside: +39.75%
Immunome
Apr 1, 2024
Maintains: Outperform
Price Target: $27 → $33
Current: $13.73
Upside: +140.35%
Sutro Biopharma
Mar 26, 2024
Maintains: Outperform
Price Target: $12 → $8
Current: $3.42
Upside: +133.92%
Fusion Pharmaceuticals
Mar 21, 2024
Reiterates: Neutral
Price Target: $24
Current: $21.42
Upside: +12.04%
bluebird bio
Mar 19, 2024
Maintains: Neutral
Price Target: $3 → $1.68
Current: $0.92
Upside: +82.05%
2seventy bio
Mar 18, 2024
Reiterates: Neutral
Price Target: $5
Current: $4.26
Upside: +17.51%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $20
Current: $8.07
Upside: +147.83%
AnaptysBio
Mar 12, 2024
Upgrades: Outperform
Price Target: $20 → $34
Current: $21.00
Upside: +61.90%
Generation Bio Co.
Mar 7, 2024
Reiterates: Outperform
Price Target: $5
Current: $2.90
Upside: +72.41%
Nuvation Bio
Mar 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $2.68
Upside: +86.57%
Mersana Therapeutics
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $2.94
Upside: +138.10%
Xencor
Feb 28, 2024
Maintains: Outperform
Price Target: $36 → $34
Current: $19.98
Upside: +70.17%
SpringWorks Therapeutics
Feb 26, 2024
Maintains: Outperform
Price Target: $60 → $70
Current: $45.53
Upside: +53.74%
Cogent Biosciences
Feb 23, 2024
Maintains: Neutral
Price Target: $5 → $10
Current: $6.02
Upside: +66.11%
G1 Therapeutics
Feb 13, 2024
Maintains: Outperform
Price Target: $5 → $4
Current: $3.99
Upside: +0.25%
Inozyme Pharma
Jan 30, 2024
Reiterates: Outperform
Price Target: $15
Current: $4.44
Upside: +237.84%
Ikena Oncology
Jan 19, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.30
Upside: +515.38%
Kiniksa Pharmaceuticals
Jan 2, 2024
Maintains: Outperform
Price Target: $23 → $25
Current: $17.88
Upside: +39.82%
Maxeon Solar Technologies
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $14 → $5
Current: $2.09
Upside: +139.23%
iTeos Therapeutics
Oct 18, 2023
Reiterates: Outperform
Price Target: $33
Current: $10.80
Upside: +205.56%
Chimerix
Aug 17, 2023
Reiterates: Outperform
Price Target: $6
Current: $0.90
Upside: +566.74%
Scholar Rock Holding
Aug 10, 2023
Reiterates: Outperform
Price Target: $24
Current: $14.53
Upside: +65.18%
Apogee Therapeutics
Aug 8, 2023
Initiates: Outperform
Price Target: $40
Current: $47.13
Upside: -15.13%
Karyopharm Therapeutics
Jul 26, 2023
Maintains: Neutral
Price Target: $7 → $4
Current: $1.06
Upside: +277.36%
Nuvalent
Jul 20, 2023
Reiterates: Outperform
Price Target: $53
Current: $66.86
Upside: -20.73%
AVROBIO
Jul 12, 2023
Downgrades: Neutral
Price Target: $2
Current: $1.21
Upside: +65.29%
NovoCure
Jun 7, 2023
Upgrades: Neutral
Price Target: $53 → $46
Current: $12.64
Upside: +264.07%
Y-mAbs Therapeutics
May 10, 2023
Upgrades: Outperform
Price Target: $5 → $13
Current: $14.71
Upside: -11.62%
Disc Medicine
Apr 26, 2023
Maintains: Outperform
Price Target: $32 → $36
Current: $27.55
Upside: +30.67%
Fennec Pharmaceuticals
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $9.21
Upside: +106.30%
Ultragenyx Pharmaceutical
Oct 29, 2018
Maintains: Outperform
Price Target: n/a
Current: $44.24
Upside: -
Boundless Bio
Oct 8, 2018
Maintains: Outperform
Price Target: n/a
Current: $11.64
Upside: -
Voyager Therapeutics
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $7.62
Upside: -
Syros Pharmaceuticals
Mar 13, 2018
Maintains: Outperform
Price Target: n/a
Current: $5.04
Upside: -
Prothena Corporation
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $20.87
Upside: -